X0306 4 2015-03-02 0 0001340652 ChemoCentryx, Inc. CCXI 0001422995 Cappel Markus J. C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 0 1 0 0 Chief Bus. Officer & Treasurer Common Stock 2015-03-02 4 M 0 14390 0.60 A 26890 D Common Stock 2015-03-02 4 S 0 14390 8.1289 D 12500 D Common Stock 2015-03-03 4 M 0 5943 0.60 A 18443 D Common Stock 2015-03-03 4 S 0 5943 7.8126 D 12500 D Common Stock 2015-03-04 4 M 0 20542 0.60 A 22043 D Common Stock 2015-03-04 4 S 0 20542 7.9197 D 12500 D Stock Option (right to buy) 0.60 2015-03-02 4 M 0 14390 0.00 D 2005-05-05 2015-05-05 Common Stock 14390 60610 D Stock Option (right to buy) 0.60 2015-03-03 4 M 0 5943 0.00 D 2005-05-05 2015-05-05 Common Stock 5943 54667 D Stock Option (right to buy) 0.60 2015-03-04 4 M 0 20542 0.00 D 2005-05-05 2015-05-05 Common Stock 20542 34125 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Shares sold are associated with stock options which will expire in May 2015. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.9525 to $8.31 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.70 to $7.96 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $7.62 to $8.03 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. As of March 2, 2015 and prior to this transaction, the option fully vested. /s/ Susan M. Kanaya, as Attorney-in-Fact 2015-03-04